ARTICLE | Clinical News
MT 100: Requested Additional Phase III trials
January 29, 2001 8:00 AM UTC
Pozen Inc. (POZN), Chapel Hill, N.C. Product: MT 100 Business: Neurological Therapeutic category: Neurotransmission, NSAID Target: Gastrointestinal tract nerves and cyclooxygenase enzymes Description:...